Bellevue Life Sciences Acquisition Corp.
Status: Live Deal
U=S+W+R
W=S@11.5
R=S/10
IPO Proceeds, $M | $69.00M |
---|---|
IPO Date | Feb 10, 2023 |
CEO | Kuk Hyoun Hwang |
Left Lead | Chardan |
IPO Cash in Trust | 101.8% |
SPAC Tenor | 9 + 6 + 6 |
IPO Sector |
Healthcare
Healthcare industry, more specifically in the biotechnology sector |
IPO Geography | Global |
Target Company | OSR Holdings |
Deal Announced | Nov 16, 2023 |
Deal Size, $M | TBD |
Deal Sector | Healthcare |
Deal Geography | Global |
SEC Filings | www.sec.gov |
Approval Vote | TBD |
Amendment Vote | Nov 12, 2024 |
BLAC
BLACU
BLACW
BLACR
Price | $11.05 |
---|---|
Last closing price | $11.05 |
H/L, today | $11.05 / $11.05 |
H/L, 52-week | $10.07 / $10.71 |
Volume, today | 26 |
Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Bellevue Life Sciences Acquisition Corp.:
- Structure and cap table
- 6 directors & officers
- 32 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
Name | Age | Title |
---|---|---|
Kuk Hyoun Hwang | 47 | CEO and Director |
David J. Yoo | 49 | CFO |
Jun Chul Whang | 58 | Director |
Phil Geon Lee | 56 | Director |
Jin Whan Park | 55 | Director |
Sang Hyun Kim | 53 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
Chardan | BR | 5,950,000 | units |
B. Riley FBR | 50,000 | ||
6,000,000 | units | ||
Up-Front UW fee | 2.00 | % | |
Deferred UW fee |
3.00 | % |
Sign in to view more advisor data.